NO813087L - Fremgangsmaate ved fremstilling av herpes simplex type i-vaksine - Google Patents
Fremgangsmaate ved fremstilling av herpes simplex type i-vaksineInfo
- Publication number
- NO813087L NO813087L NO813087A NO813087A NO813087L NO 813087 L NO813087 L NO 813087L NO 813087 A NO813087 A NO 813087A NO 813087 A NO813087 A NO 813087A NO 813087 L NO813087 L NO 813087L
- Authority
- NO
- Norway
- Prior art keywords
- extract
- vaccine
- herpes simplex
- simplex type
- dna
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 25
- 208000009889 Herpes Simplex Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title description 11
- 229940031626 subunit vaccine Drugs 0.000 claims abstract description 7
- 230000012010 growth Effects 0.000 claims abstract description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 15
- 239000004202 carbamide Substances 0.000 claims description 15
- 230000002163 immunogen Effects 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000011800 void material Substances 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 12
- 238000000605 extraction Methods 0.000 abstract description 7
- 210000003837 chick embryo Anatomy 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 8
- 238000000760 immunoelectrophoresis Methods 0.000 description 7
- 241001529453 unidentified herpesvirus Species 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal hydrogen phosphate salt Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000007143 thioglycolate medium Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/186,365 US4317811A (en) | 1980-09-11 | 1980-09-11 | Herpes simplex type 1 subunit vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
NO813087L true NO813087L (no) | 1982-03-12 |
Family
ID=22684654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO813087A NO813087L (no) | 1980-09-11 | 1981-09-10 | Fremgangsmaate ved fremstilling av herpes simplex type i-vaksine |
Country Status (10)
Country | Link |
---|---|
US (1) | US4317811A (de) |
EP (1) | EP0048201B1 (de) |
JP (1) | JPS5780326A (de) |
AT (1) | ATE12583T1 (de) |
CA (1) | CA1174599A (de) |
DE (1) | DE3169848D1 (de) |
DK (1) | DK401981A (de) |
FI (1) | FI73596C (de) |
IE (1) | IE51553B1 (de) |
NO (1) | NO813087L (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4388035A (en) * | 1979-08-01 | 1983-06-14 | Bud Antle, Inc. | Dibble tube soil plug planter |
US4540669A (en) * | 1980-09-11 | 1985-09-10 | Merck & Co., Inc. | Herpes simplex type I subunit vaccine |
US4554159A (en) * | 1981-11-12 | 1985-11-19 | Institute Merieux | Vaccine and method of immunizing against herpes simplex virus (types 1 and 2) |
DE3378611D1 (en) * | 1982-03-24 | 1989-01-12 | Univ Birmingham | Vaccine against dna viruses |
CA1201987A (en) * | 1982-03-24 | 1986-03-18 | Gordon R.B. Skinner | Vaccine against dna viruses |
NZ209308A (en) * | 1983-08-30 | 1991-08-27 | Genentech Inc | Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein |
US7264817B1 (en) | 1983-08-30 | 2007-09-04 | Genentech, Inc. | Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it |
JPS6051120A (ja) * | 1983-08-31 | 1985-03-22 | Chemo Sero Therapeut Res Inst | 単純ヘルペスサブユニットワクチン |
US4618578A (en) * | 1984-07-17 | 1986-10-21 | Chiron Corporation | Expression of glycoprotein D of herpes simplex virus |
US5244792A (en) * | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
US5171568A (en) * | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
US5612041A (en) * | 1984-07-17 | 1997-03-18 | Chiron Corporation | Recombinant herpes simplex gD vaccine |
JPS6153226A (ja) * | 1984-08-24 | 1986-03-17 | Chemo Sero Therapeut Res Inst | 単純ヘルペスサブユニツトワクチンの精製方法 |
US4761470A (en) * | 1985-12-16 | 1988-08-02 | Merck & Co., Inc. | Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody |
US5955088A (en) * | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
EP1027426A4 (de) * | 1997-10-31 | 2006-04-19 | Merck & Co Inc | Methode für verbessertes mischen einer varicella-infizierten zellkultur in rollflaschen |
US20030045467A1 (en) * | 2001-01-05 | 2003-03-06 | Tihamer Orban | Autoantigen composition |
WO2007127787A2 (en) * | 2006-04-25 | 2007-11-08 | Joslin Diabetes Center, Inc. | Insulin autoantigen-specific regulatory cd4+ t cells |
RU2552341C1 (ru) * | 2014-02-26 | 2015-06-10 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) | Фармацевтическая композиция для получения антигерпетической поливакцины и лекарственной формы на ее основе |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI66020C (fi) * | 1977-09-19 | 1984-08-10 | Merck & Co Inc | Foerfarande foer framstaellning av antigeniska immunogeniska subunits av hsv-1 och hsv-2 |
-
1980
- 1980-09-11 US US06/186,365 patent/US4317811A/en not_active Expired - Lifetime
-
1981
- 1981-09-02 FI FI812704A patent/FI73596C/fi not_active IP Right Cessation
- 1981-09-09 CA CA000385518A patent/CA1174599A/en not_active Expired
- 1981-09-09 IE IE2096/81A patent/IE51553B1/en unknown
- 1981-09-10 AT AT81401407T patent/ATE12583T1/de not_active IP Right Cessation
- 1981-09-10 EP EP19810401407 patent/EP0048201B1/de not_active Expired
- 1981-09-10 NO NO813087A patent/NO813087L/no unknown
- 1981-09-10 DK DK401981A patent/DK401981A/da not_active Application Discontinuation
- 1981-09-10 DE DE8181401407T patent/DE3169848D1/de not_active Expired
- 1981-09-11 JP JP14372681A patent/JPS5780326A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IE812096L (en) | 1982-03-11 |
DE3169848D1 (en) | 1985-05-15 |
FI73596C (fi) | 1987-11-09 |
US4317811A (en) | 1982-03-02 |
EP0048201A3 (en) | 1982-09-15 |
ATE12583T1 (de) | 1985-04-15 |
DK401981A (da) | 1982-03-12 |
EP0048201A2 (de) | 1982-03-24 |
EP0048201B1 (de) | 1985-04-10 |
FI73596B (fi) | 1987-07-31 |
JPS5780326A (en) | 1982-05-19 |
FI812704L (fi) | 1982-03-12 |
CA1174599A (en) | 1984-09-18 |
IE51553B1 (en) | 1987-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO813087L (no) | Fremgangsmaate ved fremstilling av herpes simplex type i-vaksine | |
US6048537A (en) | Method for preparing an influenza virus, antigens obtained and applications thereof | |
US4374127A (en) | Herpes sub unit vaccine | |
FI85222B (fi) | Hund parvovirusstam och foerfarande foer framstaellning av ett hund parvovirusvaccin. | |
NO153692B (no) | Fremgangsmaate ved fremstilling av en antigen, immunogen subenhet av herpes simplex type 1 (hsv1) eller type 2 subenhet (hsv2) | |
CN113308441B (zh) | 一株猫疱疹病毒i型病毒株及其应用 | |
Cappel et al. | Clinical efficacy of a herpes simplex subunit vaccine | |
RU2378014C2 (ru) | Ассоциированная вакцина против парагриппа-3, инфекционного ринотрахеита и коронавирусной инфекции крупного рогатого скота эмульсионная инактивированная | |
EP0011864A1 (de) | Abgeschwächter Stamm des bei Feliden infektiöse Peritonitis verursachenden Virus, Verfahren zu seiner Herstellung und ihn enthaltender Impfstoff | |
CN106563125A (zh) | 鸭甲肝病毒ⅲ型复合物活疫苗及其制备方法 | |
Wu et al. | Antigenic and immunogenic characterization of infectious bronchitis virus strains isolated in China between 1986 and 1995 | |
US4540669A (en) | Herpes simplex type I subunit vaccine | |
HU200696B (en) | Process for producing combined vaccine | |
van den Hurk | Protection of turkeys against haemorrhagic enteritis by monoclonal antibody and hexon immunization | |
US20070111211A1 (en) | Integrated viral complexes, methods of production thereof, vaccines containing same and methods of use thereof | |
US3098011A (en) | Process of producing a vaccine against distemper | |
RU2294760C2 (ru) | Вакцина инактивированная сорбированная против ящура типа а | |
US3432391A (en) | Attenuated infectious canine hepatitis live virus vaccine and method of producing same | |
CN110237245B (zh) | 一种禽流感病毒样颗粒抗原、及其制备方法和应用 | |
RU2279474C1 (ru) | Штамм тк-а/к вируса инфекционного ринотрахеита крупного рогатого скота для изготовления вакцинных и диагностических препаратов | |
NL7908687A (nl) | Infectieuze bronchitis vaccins voor pluimvee en werkwijze voor het bereiden van dergelijke vaccins. | |
Jones et al. | Isolation of infectious laryngotracheitis virus from proximal femora of lame broiler chickens | |
RU2144562C1 (ru) | Штамм "вниизж/№ 110" вируса герпеса индеек для изготовления вакцины против болезни марека | |
CN117069829A (zh) | 一种猫泛白细胞减少症卵黄抗体及其制备方法和应用 | |
EP0591384A1 (de) | Abgeschwächter rückmutierter virusimpfstoff gegen mareks krankheit serotyp-1 |